Evidence map›Paper›PMID 36335534›Full record

ArticleInternational journal of hematology2023

Age and allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia.

Masamitsu Yanada, Satoshi Yamasaki, Takaaki Konuma, Shohei Mizuno, Naoyuki Uchida, Daishi Onai, Takahiro Fukuda, Masatsugu Tanaka, Yukiyasu Ozawa, Tetsuya Eto and 9 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Masamitsu YanadaDepartment of Hematology and Cell Therapy, Aichi Cancer Center, 1-1 Kanokoden, Chikusa-ku, Nagoya, 464-8681, Japan. myanada@aichi-cc.jp.ORCID http://orcid.org/0000-0003-1602-9775
Satoshi YamasakiKyusyu University Beppu Hospital, Beppu, Japan.
Takaaki KonumaThe Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Shohei MizunoAichi Medical University, Nagakute, Japan.
Naoyuki UchidaToranomon Hospital, Tokyo, Japan.
Daishi OnaiTokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
Takahiro FukudaNational Cancer Center Hospital, Tokyo, Japan.
Masatsugu TanakaKanagawa Cancer Center, Yokohama, Japan.
Yukiyasu OzawaJapanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital, Nagoya, Japan.
Tetsuya EtoHamanomachi Hospital, Fukuoka, Japan.
Kazuhiro IkegameHyogo College of Medicine, Nishinomiya, Japan.
Masashi SawaAnjo Kosei Hospital, Anjo, Japan.
Yuta KatayamaHiroshima Red Cross Hospital and Atomic-Bomb Survivors Hospital, Hiroshima, Japan.
Toshiro KawakitaNational Hospital Organization Kumamoto Medical Center, Kumamoto, Japan.
Makoto OnizukaTokai University School of Medicine, Isehara, Japan.
Yoshinobu KandaJichi Medical University, Shimotsuke, Japan.
Tatsuo IchinoheResearch Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
Yoshiko AtsutaAichi Medical University, Nagakute, Japan.
Shingo YanoThe Jikei University School of Medicine, Tokyo, Japan.

Funding

Japan Agency for Medical Research and Development 19ek0510023h0003
6 · The paper itself

Abstract

Although several studies have reported significant effects of patient age on outcomes of allogeneic hematopoietic cell transplantation (HCT), the prognostic relevance of age must be determined separately for myeloablative conditioning (MAC) and reduced-intensity conditioning (RIC). We analyzed Japanese nationwide transplantation registry data of patients aged 20-79 years with acute myeloid leukemia who underwent allogeneic HCT using MAC (n = 7525) or RIC (n = 3154) between 2008 and 2019. Patient were divided into six groups by age, with each group representing a decade, and overall survival (OS), relapse, and non-relapse mortality (NRM) were compared between adjacent age groups. The adverse impact of age on OS increased each decade starting at age 40 among patients receiving MAC, but only differed significantly between patients in their 50s and 60s among those receiving RIC. In patients receiving both MAC and RIC, the detrimental effect of advanced age on OS was accompanied by an increased risk of NRM. These findings show that age affects NRM and OS significantly, but differs depending on conditioning intensity. RIC mitigates the adverse prognostic impact of older age and is thus considered a reasonable option for older patients.

Indexed as

Graft vs Host DiseaseHematopoietic Stem Cell TransplantationLeukemia, Myeloid, AcuteAdultChronic DiseaseHumansPrognosisRecurrenceRetrospective StudiesTransplantation ConditioningAcute myeloid leukemiaAgeAllogeneic hematopoietic cell transplantationConditioning intensity

Identifiers

PMID36335534

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.